l
 

INTERACTIVE
WEBINAR

 
Call-in teleconferencing 
 
Video demonstrations included in the presentation
 
 
 
610-399-4897
 

 

 

 
 

:
  

Evaluating Contamination Concerns forAseptic Manufacturing and Sterility Testing Isolators


July 29, 2010 WEBINAR
NOON - 1:30 pm EDT
 

Barrier Isolators were created to exclude the principal source of microbial contamination from filling lines, i.e., human operators. In large part the use of barrier isolators has be highly successful. However, isolators are not ‘magic boxes’ and must be utilized in specific ways. This webinar will explain how to properly operate both sterility test isolators and production isolators, so that microbial contamination of sterility tests and lots of sterile product is avoided. Improper use of a sterility test isolator may result in false-positive test results.  Failure to operate a production isolator properly may result in product contamination.

What you will learn about:

  • The Regulatory view of Sterility Testing in Isolators
  • How to properly investigate Sterility Test Positives
  • Expected Isolator Environments
  • Proper decontamination of Production & Sterility Testing Isolators
  • Proper decontamination of Sterility Test Units and testing materials
  • The best type of disinfectants to use
  • Proper maintenance of Production & Sterility Testing Isolators
  • Acceptable training frequencies for operators

Several case studies will be presented that illustrate real failures for sterility test isolators and production isolators. Advice will be given on how to avoid these sort of unfortunate scenarios.

Who should attend?

  • Quality Assurance/Quality Control [especially Microbiologists]
  • Technical Services/Validation
  • Production
  • Facility Engineers

FEE:
$365 for one person.
$700 for 3-5 people
$999 for 6-10 people 

 

Instructor:

Ken Muhvich, Ph.D., Principal Consultant, Micro-Reliance LLC, regularly provides sterility assurance and microbial quality advice to manufacturers of drugs, biologics and devices. Since leaving the FDA in 1997, where he serves as a Review Microbiologist in the Office of Generic Drugs, he has worked for more than 200 sterile product manufacturers. He is frequently involved in guiding companies in sterile process design and validation. He is also often called upon to investigate batch sterility failures or to review completed sterility failure investigations. He is the co-leader of the Parenteral Drug Association’s Sterile Processing Interest Group.

  
 
REGISTER NOW!  CLICK HERE!
610-399-4897
 
ECCWEB196